A Real-world study to evaluate the treatment satisfaction of patients on Hizentra, a 20% subcutaneous immunoglobulin for primary immunodeficiency

Trial Profile

A Real-world study to evaluate the treatment satisfaction of patients on Hizentra, a 20% subcutaneous immunoglobulin for primary immunodeficiency

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2018 New trial record
    • 05 Mar 2018 Results (n=371) assessing subcutaneous IG (SCIG) use in previously untreated primary immunodeficiency (PI) patients through Treatment Satisfaction Questionnaire for Medication score presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top